Heiden
Capital Markets Global Healthcare Conference
2013
Annual Healthcare Conference on
update, followed by a question and answer session with investors.
A live webcast of the presentations will be accessible through the
Investors section of the company’s website at www.amagpharma.com.
Following the conferences, the webcasts will be archived on the
Pharmaceuticals, Inc.
About AMAG
manufactures and markets Feraheme® (ferumoxytol) Injection for
Intravenous (IV) use in
growth of its lead product, AMAG intends to expand its portfolio with
additional commercial-stage specialty pharmaceuticals. The company is
seeking complementary products that leverage the company’s commercial
footprint and focus on hematology and oncology centers and hospital
infusion centers. For additional company information, please visit www.amagpharma.com.
Source:
AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303